Literature DB >> 16507760

Abeta peptide immunization restores blood-brain barrier integrity in Alzheimer disease.

Dara L Dickstein1, Kaan E Biron, Maki Ujiie, Cheryl G Pfeifer, Andrew R Jeffries, Wilfred A Jefferies.   

Abstract

Immunization with amyloid beta (Abeta) peptides or passive immunization with antibodies against Abeta has been reported to reduce plaque burden, neuritic dystrophy, early Tau pathology, microgliosis as well as reversing learning and memory deficits. This has created a central paradox: how does vaccination in peripheral tissues reduce plaque burden in the brain? No single explanation for these phenomena has yet been presented. To reconcile these observations, we demonstrate that the integrity of the blood-brain barrier (BBB), a structural barrier between the brain and the blood, is compromised in Tg2576 Alzheimer disease (AD) model mice. We immunized Tg2576 mice with Abeta before and after the onset of AD-type neuropathology and observed that BBB permeability, amyloid burden, and microgliosis are decreased in immunized mice. It is concluded that the integrity of the BBB is disrupted in AD mice, and after Abeta immunization the immune system clears Abeta from sources in the brain as it would in peripheral organs lacking barriers. Once Abeta is removed, the integrity of the BBB is restored. The data therefore provide an intellectual framework for understanding how the immune system can clear amyloid deposits from AD brains and suggest new strategies for limiting disease progression in amyloidopathies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16507760     DOI: 10.1096/fj.05-3956com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  44 in total

1.  Clearance of amyloid-β peptides by microglia and macrophages: the issue of what, when and where.

Authors:  Aaron Y Lai; Joanne McLaurin
Journal:  Future Neurol       Date:  2012-03-01

2.  Characterization of the role of metallothionein-3 in an animal model of Alzheimer's disease.

Authors:  Yasmina Manso; Javier Carrasco; Gemma Comes; Gabriele Meloni; Paul A Adlard; Ashley I Bush; Milan Vašák; Juan Hidalgo
Journal:  Cell Mol Life Sci       Date:  2012-06-22       Impact factor: 9.261

Review 3.  Metallothionein and brain inflammation.

Authors:  Yasmina Manso; Paul A Adlard; Javier Carrasco; Milan Vašák; Juan Hidalgo
Journal:  J Biol Inorg Chem       Date:  2011-06-16       Impact factor: 3.358

Review 4.  Developmental and pathological angiogenesis in the central nervous system.

Authors:  Mario Vallon; Junlei Chang; Haijing Zhang; Calvin J Kuo
Journal:  Cell Mol Life Sci       Date:  2014-04-24       Impact factor: 9.261

Review 5.  Apolipoprotein E in Alzheimer's disease and other neurological disorders.

Authors:  Philip B Verghese; Joseph M Castellano; David M Holtzman
Journal:  Lancet Neurol       Date:  2011-03       Impact factor: 44.182

Review 6.  Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier.

Authors:  William A Banks
Journal:  Adv Drug Deliv Rev       Date:  2011-12-17       Impact factor: 15.470

7.  Abeta immunotherapy protects morphology and survival of adult-born neurons in doubly transgenic APP/PS1 mice.

Authors:  Barbara Biscaro; Olle Lindvall; Christoph Hock; Christine T Ekdahl; Roger M Nitsch
Journal:  J Neurosci       Date:  2009-11-11       Impact factor: 6.167

8.  Central and peripheral administration of antisense oligonucleotide targeting amyloid-β protein precursor improves learning and memory and reduces neuroinflammatory cytokines in Tg2576 (AβPPswe) mice.

Authors:  Susan A Farr; Michelle A Erickson; Michael L Niehoff; William A Banks; John E Morley
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

9.  Soluble aggregates of the amyloid-beta protein selectively stimulate permeability in human brain microvascular endothelial monolayers.

Authors:  Francisco J Gonzalez-Velasquez; Joseph A Kotarek; Melissa A Moss
Journal:  J Neurochem       Date:  2008-09-16       Impact factor: 5.372

10.  Brain ischemia and ischemic blood-brain barrier as etiological factors in sporadic Alzheimer's disease.

Authors:  Ryszard Pluta; Marzena U Amek
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.